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Abstract
Background: The increase in bacterial resistance to antibiotics impels the development of new anti-bacterial
substances. Mutacins (bacteriocins) are small antibacterial peptides produced by Streptococcus mutans showing
activity against bacterial pathogens. The objective of the study was to produce and characterise additional
mutacins in order to find new useful antibacterial substances.
Results: Mutacin F-59.1 was produced in liquid media by S. mutans 59.1 while production of mutacin D-123.1 by
S. mutans 123.1 was obtained in semi-solid media. Mutacins were purified by hydrophobic chromatography. The
amino acid sequences of the mutacins were obtained by Edman degradation and their molecular mass was
determined by mass spectrometry. Mutacin F-59.1 consists of 25 amino acids, containing the YGNGV consensus
sequence of pediocin-like bacteriocins with a molecular mass calculated at 2719 Da. Mutacin D-123.1 has an
identical molecular mass (2364 Da) with the same first 9 amino acids as mutacin I. Mutacins D-123.1 and F-59.1
have wide activity spectra inhibiting human and food-borne pathogens. The lantibiotic mutacin D-123.1 possesses
a broader activity spectrum than mutacin F-59.1 against the bacterial strains tested.
Conclusion: Mutacin F-59.1 is the first pediocin-like bacteriocin identified and characterised that is produced by
Streptococcus mutans. Mutacin D-123.1 appears to be identical to mutacin I previously identified in different strains
of S. mutans.
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Background
The excessive and often inappropriate use of antibiotics
leads to a continuous increase and spread of antibiotic
resistance among bacteria, thus making it imperative to
discover and carefully use new antibacterial substances
[1]. Bacteriocins are bacterial ribosomally synthesised
proteinaceous substances with strong antibacterial activ-
ity, excellent structural stability, low immunogenicity,
while resistance does not develop frequently [2-4]. One
general mechanism of action of bacteriocins involves
pore formation in target cells leading to the leakage of
small molecules and cell death [4,5]. Bacteriocins from
Gram positive bacteria can be grouped into three
classes: class I which includes lantibiotics containing
post-translationally modified amino acids such as
lanthionine and dehydrated amino acids, class II non-
lantibiotics, containing only common amino acids and
class III containing bacteriocins with higher molecular
mass (> 10 kDa) [2,4]. Lantibiotics (class I) are divided
into type A (elongated linear peptides) and type B (glob-
ular peptides) [5]. Class II is subdivided into three sub-
classes, namely, class IIa (pediocin-like bacteriocins),
class IIb (two-peptide bacteriocins) and class IIc (other
one-peptide bacteriocins) [2]. The biosynthesis of bac-
teriocins requires the translation of the prepeptide, post-
translational modifications such as dehydration and
cyclisation reactions to form the thioether bridges in
lantibiotics and cleavage of the leader peptide during
transport outside of the cell [2,4]. Streptococcus mutans,
a human indigenous oral bacterial species, is known to
produce bacteriocins named mutacins [6]. It is believed
that production of such mutacins may confer to
S. mutans an advantage against competitive species liv-
ing in the same niche [6]. To date, mutacins from class
I and class II have been purified and characterised: the
mono-peptide lantibiotic (mutacin B-Ny266), the di-
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non-lantibiotic (mutacin N) and the di-peptide non-lan-
tibiotic (mutacin IV) [for review see reference 6 and
references therein]. Production of more than one muta-
cin by a given strain has been experimentally demon-
strated for several strains and is also predicted by
bioinformatic analysis of sequenced strain genomes [6].
Mutacin-producing strains and some of their purified
peptides have shown activity against Gram positive and
some Gram negative bacteria in vitro and in vivo [7-9].
Because of their biochemical diversity and activity spec-
tra, many applications can be expected for mutacins as
antibiotics or food preservatives [3,10].
The main objective of our research is to further char-
acterise mutacins to uncover new useful antibacterial
substances active against bacterial pathogens. We pre-
viously classified 86 mutacin-producing strains into 24
groups (designated A to X) and subsequently seven clus-
ters of activity were defined from the 24 type strains.
This grouping was based only on their activity spectra
towards other mutacinogenic strains and against various
bacterial species including pathogens [8,11]. S. mutans
59.1 and 123.1 were clearly distinct in their activity
spectra and the mutacins produced by these strains
were not genetically related to the well known lantibio-
tics (nisin, gallidermin, epidermin, subtilin) nor to pre-
viously well characterised mutacins (B-Ny266, B-JH1140
(mutacin III), J-T8 (mutacin II), H-29B) by using specific
molecular probes [8,12]. We present here results on the
production, purification and characterisation of muta-
cins F-59.1 and D-123.1.
Results
Mutacin F-59.1 was produced in SWP and the activity
was measured as 400 AU/mL while production of muta-
c i nD - 1 2 3 . 1w a sa c h i e v e di ns e m i - s o l i dm e d i u mb y
using tryptic soy with yeast extract containing agarose.
Activity of the crude mutacin D-123.1 preparation was
measured to be 200 AU/mL.
Mutacins D-123.1 and F-59.1 were purified by succes-
sive steps of hydrophobic chromatography. Active frac-
tions of mutacin F-59.1 purification were recovered with
an elution gradient of 50%-60% methanol in 10 mM
HCl (Figure 1) and those of mutacin D-123.1 with a
60%-70% gradient (Figure 2). The final specific activities
were 3.2 × 10
5 AU/mg for the purified mutacin F-59.1
and of 1.6 × 10
5 AU/mg for the purified mutacin D-
123.1 (Table 1).
A total of 25 amino acids were sequenced for mutacin
F-59.1 and its identity with pediocin-like bacteriocins was
confirmed by multiple alignment (Figure 3). The
sequence revealed high levels of similarity to class IIa
bacteriocins with the presence of the five residues of the
common consensus sequence -YGNGV- and the two
conserved cysteine residues at positions 9 and 14. The
substitution of unidentified amino acids (annotated X) in
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Figure 1 Elution profile of mutacin F-59.1 on RP-HPLC. Active peak is boxed.
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Page 2 of 10the mutacin F-59.1 sequence with consensus amino acids
f o u n di no u ra l i g n m e n t( F i g u r e3 )a n dt h o s eo fo t h e r s
[2,13], revealed that the following N-terminal sequence
KYYGNGVTCGKHSCSVDWSKATTNI matches the
molecular mass determined by MALDI-TOF MS analysis
(2720 Da +/- 2 Da, due to the formation of the current
disulfide bridge found between C9 and C14 in pediocin-
like bacteriocins [2], (Figure 4)). The isoelectric point of
mutacin F-59.1 (pI = 8.71) and secondary structure pre-
diction with this sequence correlate well with other class
IIa bacteriocins (Figure 3) [2,4].
The molecular mass for mutacin D-123.1 was com-
puted to be 2364 Da (Figure 5). However, sequencing of
the mutacin D-123 proved to be problematic. Edman
degradation of native mutacin D-123.1 was blocked after
the first residue (F). The sequence of only the first 9
amino acids was clearly obtained after the derivatisation
procedure, but with at least two peaks at each cycle.
The growth of M. luteus ATCC 272 was inhibited
immediately following the addition of a purified pre-
paration of mutacin F-59.1 at 160 AU/mL as the viable
count decreased rapidly and dropped to zero compared
to the control. Over an incubation period of 24 h, the
viable count of the test culture remained unchanged,
suggesting that mutacin F-59.1 activity was bactericidal
at the concentration tested (Figure 6).
The activity spectra observed for mutacins F-59.1 and
D-123.1 show inhibition of a wide range of pathogenic
bacteria including Bacillus spp., Enterococcus spp., Lis-
teria spp.,
Staphylococcus spp. and Streptococcus spp. (Table 2).
Discussion
The inhibitory activity produced by the fermentation of
S. mutans 59.1 in SWP did not come from release of
pediocin already present in the whey proteins or perme-
ate used to make the medium because no inhibitory
activity in SWP was detected from non-fermented nor
purified medium against M. luteus ATCC 272 and also
because many other S. mutans s t r a i n sw e r eu n a b l et o
produce an inhibitory activity by fermentation of the
same medium [14,15].
Of all the current microbiological broth media com-
monly used for the growth of Streptococcus sp., none
Figure 2 Elution profile of mutacin D-123.1 on RP-HPLC. Active peak is boxed.
Table 1 Purification of mutacins F-59.1 and D-123.1 by hydrophobic chromatography
Step Volume
(mL)
Activity
(AU/mL)
Total Protein
(mg)
Total activity
(AU.10
3)
Specific activity
(AU/mg)
Yield
(%)
Purification
(fold)
mutacin F-59.1
Culture supernatant 1000 400 10000 400 40 100 1
Sep-Pak C18 95 3200 3000 304 101 76 2.5
C18 RP-HPLC 2 16000 0.1 32 3.2 × 10
5 88 × 1 0
3
mutacin D-123.1
Culture supernatant 675 200 4320 135 31 100 1
Sep-Pak C18 50 1600 8 80 1 × 10
4 59 320
C18 RP-HPLC 1 800 0.005 0.8 1.6 × 10
5 0.2 5120
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Page 3 of 10permitted the production of a detectable level of muta-
cin activity by S. mutans 123.1. Activity of mutacin D-
123.1 was only detected after growth on solid medium.
The production of some bacteriocins and mutacins is
controlled by quorum sensing mechanisms which are
better expressed when cells are grown at high density
compared to lower cell density obtained in liquid cul-
ture [6]. For the isolation of mutacin D-123.1, agarose
was preferred over agar as agar may contain compounds
interfering with accurate detection of mutacin activity
[16]. The nature of these compounds is still unknown,
but divalent anions such as sulfates are suspected. As
seen in previous work with other mutacins, purification
yields were low (Table 1) and additional chromato-
graphic steps will be necessary to improve yields and
purity. The higher concentration of methanol used to
recover mutacin D-123.1 suggests that the peptide is
more hydrophobic than mutacin F-59.1. Collected sam-
ples of pure mutacin D-123.1 were very viscous because
they probably retain part of the polymeric sugars from
the agarose. However, with the methods used here, suffi-
cient amounts of the substances were collected to carry
Query seq Mutacin F-59.1 1 --------------------KYYGNGVTCGKHSXSVDWXKXTXXX-------------------  25
Pediocin ACO56765 1 -------------ANIIGG-KYYGNGVTCGKHSCSVDWGKATTCIINNGAMAWATGGHQGNHKC  50
Prepediocin AcH AAC60413 1 -MKKIEKLTEKEMANIIGG-KYYGNGVTCGKHSCSVDWGKATTCIINNGAMAWATGGHQGNDKC  62
Pediocin PA-1 AAB23877 1 --------------------KYYGNGVTCGKHSCSVDWGKATTCIINNGAMAXATGGHQGNHKX  44
Coagulin AAG28763 1 -MKKIEKLTEKEMANIIGG-KYYGNGVTCGKHSCSVDWGKATTCIINNGAMAWATGGHQGTHKC  62
Plantaricin 423  AAL09346 1 -MKKIEKLTEKEMANIIGG-KYYGNGVTCGKHSCSVDWGKATTCIINNGAMAWATGGHQGNHKC  62
Sakacin P P35618 1 -MEKFIELSLKEVTAITGG-KYYGNGVHCGKHSCTVDWGTAIGNIGNNAAANWATGGNAGWNK-  61
Prebacteriocin SkgA2 ZP_03958670 1 -MENKKKLTKADLAKVTGGSRYYGNGVTCGKHKCTVNWGQAWTCGVNRLAN-------FGHGNC  56
Bavaricin A P80953 1 --------------------KYYGNGVHXGKHSXTVDWGTAIGNIGNNAAANXATGXNAGG---  41
Enterocin-HF P86183 1 --------------------KYYGNGVSCNKKGCSVDWGKAIGIIGNNAAANLTTGGKAAW-AC  43
Piscicolin 126  ACD01989 1 -MKTVKELSVKEMQLTTGG-KYYGNGVSCNKNGCTVDWSKAIGIIGNNAAANSTTGGAAGWNKR  62
Mundticin KS BAB88211 1 ----MKKLTAKEMSQVVGG-KYYGNGVSCNKKGCSVDWGKAIGIIGNNSAANLATGGAAGW-KS  58
Enterocin CRL35 AAQ95741 1 ----MKKLTSKEMAQVVGG KYYGNGVSCNKKGCSVDWGKAIGIIGNNSAANLATGGAAGW-KS  58
Consensus sequence 1 ----MKKLTSKEMAQVVGG KYYGNGVSCNKKGCSVDWGKAIGII
CCHHHHHHHHHCCTTCCCCCHCCCC
    CCEETEEEECCEEEEECTTCCEEEEEETTEEEEEETCCCTCCCC
Figure 3 Multiple sequence alignment of mutacin F-59.1 with homologous class IIa bacteriocins. Consensus sequence appears in bold.
Some of the leader sequences are shown with the double glycine motif. Underneath appears in italic the predicted secondary structure for
mutacin F-59.1 and pediocin PA-1. Output classification is as follows: H, alpha-helix; E, extended strand; T, turn; C, the rest [43]. Accession
numbers refer to bacteriocins in the protein database from the NCBI (AAC60413, [44]; AAB23877, [45]; AAG28763, [46]; AAL09346, [47]; P35618,
[48]; P80953, [49]; ACD01989, [50]; BAB88211, [51]; AAQ95741, [52]).
Major peak is at 2720 Da
Figure 4 MALDI-TOF-MS spectra obtained for pure mutacin F-59.1.
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Page 4 of 10out a preliminary characterisation of the peptides but
the evaluation of their antibacterial spectrum was some-
what restricted.
The sequence of mutacin F-59.1 (25 residues) was
shorter than the generally recognised size for pediocin-
like bacteriocins which is between 37 and 48 residues
[2,13]. This may be due to peptidase activity of the
strain. Fifty three peptidases or peptidase homologues
are found in the genome of S. mutans UA159 using the
MEROPS database [17,18]http://merops.sanger.ac.uk.
The pediocin-like bacteriocin sequence could thus be a
substrate in its 25
th position for many of these pepti-
dases. MALDI-TOF MS analysis revealed a major peak
with an isotopic mass [M+H]
+ of 2720 Da for mutacin
F-59.1 (Figure 4). This mass represents the lowest
reported mass for an active naturally-produced pedio-
cin-like bacteriocin after the study of Bhunia et al. [19].
The length of mutacin F-59.1 was sufficient to confer
antimicrobial activity against several bacterial genera
including Bacillus spp., Enterococcus spp., Lactococcus
spp., Micrococcus spp., Listeria spp., and Streptococcus
spp. (Table 2). Salvucci et al. [20] reported activity of
short peptides derived from the NH2-terminus of enter-
ocin CRL35 and other class IIa bacteriocins, suggesting
that the C-terminus of pediocin-like bacteriocins is not
essential for their inhibitory activity. Also, an active anti-
microbial region in the NH2-terminus of this class of
bacteriocin was identified by a bioinformatic approach
[21]. The C-terminus section is known to confer specifi-
city in the activity spectra of class IIa bacteriocins and
to interact with their cognate immunity proteins [22].
Pediocin-like bacteriocins are unstructured in an aqu-
eous solution and become structured when in contact
with membrane-mimicking entities [2]. The electrostatic
distribution along the molecule is highly polarized with
most of the cationic residues concentrated in the N-
terminal region. In the model class IIa bacteriocin saka-
cin P, the N-terminal residues in positions 7-9 (V-T-C)
and 15-17 (S-V-D) are predicted to form an anti-parallel
b-sheet-like structure stabilised by a conserved disulfide
bridge, followed by a hairpin-like structure that consists
of an amphiphilic a-helix in position 18-25 (W-G-K-A-
I-G-I-I). A second a-helix normally found in pediocin-
like bacteriocins at position 29-32 (S-A-A-N) with the
C-terminal tail (residue 33 to the end) that folds back
onto the central a-helix is absent in mutacin F-59.1. A
flexible hinge is found in position 17 (D) between the
N-terminal b strands and the hairpin-like C-terminal
region [23]. Studies on the conformational changes of
pediocin in an aqueous medium were conducted by
Gaussier et al. [24]. The authors concluded that the flex-
ibility of the protein ensures its activity and that the
aggregation of the C-terminus caused a loss of activity.
Lack of the C-terminus in mutacin F-59.1 should pre-
vent the formation of such aggregates and does not dis-
rupt the activity of the molecule. The predicted
secondary structure of mutacin F-59.1 appears to differ
slightly from that of pediocin PA-1. An a-helix is
formed between residues 2 to 11 and a turn is found at
position 14-15 as compared to position 18-19 of pedio-
cin PA-1. The positions of the disulfide bridges were
correctly predicted between positions C9-C14 for
Major peak is at 2364 Da
Figure 5 MALDI-TOF-MS spectra obtained for pure mutacin D-123.1.
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Page 5 of 10mutacin F-59.1 and between positions C9-C14 and C24-
C44 for pediocin PA-1 (data not shown).
As for mutacin I, Edman degradation of native mutacin
D-123.1 was blocked after the first residue (F), suggesting
that the second residue (probably an S residue) was dehy-
drated as dehydrated amino acids in lantibiotics were
shown to block Edman degradation [25,26]. Following
close inspection using the relative intensity of each peak
as a reference and the fact that ethanethiol treatment
broke mutacin I into two fragments according to Qi et al.
[25], therefore creating two N-termini peptides in the
mixture to be sequenced, we reasoned and found the fol-
lowing partial amino acid sequence for mutacin D-123.1:
F-SEC-SEC/DSER-L-SEC-L-SEC-SEC/DSER-L-(...)-P-
SEC/DSER-F-N-SEC/DSER-Y-SEC-SEC. According to
Meyer et al. [26], SEC results from the conversion of a
dhA while a SEC signal accompanied by a DSER signal
indicates residues involved in Lan (A) formation, making
the thioether bridge. Based on these observations and by
analogy to mutacin I, a more accurate, partial and trun-
cated sequence with structural thioether bridges posi-
tions can be proposed for mature mutacin D-123.1. The
sequence of the two separate fragments obtained for the
mutacin D-123.1 is as follows:
Nter-F-S-S-L-S-L-C-S-L-(...)-P-S-F-N-S-Y-C-C
Nter-F-dhA-A-L-dhA-L-A-A-L-(...)-P-A-F-N-A-Y-A-
A.
(A) residues are involved in Lan formation. At this
stage, an accurate thioether bridge pattern of mutacin
D-123.1 cannot be proposed unambiguously. The mass
of mutacin D-123.1 matched exactly that calculated for
the lantibiotic mutacin I produced by S. mutans CH43
and UA140 (2364 Da) [25,27]. This observation
strengthens the apparent identity between mutacin D-
123.1 and mutacin I.
The activity spectra of purified mutacins F-59.1 and
D-123.1 are in accordance with the antibacterial activity
spectra of the respective producing strains inhibiting
Bacillus cereus, Enterococcus spp., Listeria monocyto-
genes, Staphylococcus spp. and Streptococcus spp. using
the deferred antagonism assay and thus observed for
other purified pediocin-like bacteriocins and mutacins
[2,7,8,13,19,22,27]. However, some of the strains tested,
particularly Listeria spp., were less sensitive to the activ-
ity of purified mutacin F-59.1 than to the producer
strain itself [8]. This may be due to the production by
CFU/mL 
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Figure 6 Inhibitory action of purified mutacin F-59.1 against
Micrococcus luteus ATCC 272. Growth of cells was followed by
measuring the viable count (CFU/mL) following the addition of
purified mutacin F-59.1 (1600 AU/mL) (square line) or not for control
(diamond line).
Table 2 Inhibitory spectra of purified mutacins F-59
Indicator bacteria Activity of mutacin (AU/mL)
D-123.1 F-59.1
Bacillus cereus ATCC 2 n.t.
a 400
Bacillus subtilis ATCC 6051 n.t. 400
Enterococcus faecium ATCC 19434 0 1600
Enterococcus faecalis ATCC 27235 400 200
Enterococcus hirae ATCC 8043 200 200
Lactobacillus salivarius SMQ 876 n.t. 0
Lactococcus lactis ATCC 11454 400 400
Listeria monocytogenes ATCC 15313 400 200
b
L. monocytogenes ATCC 700301 ScottA 200 200
b
L. monocytogenes ATCC 700302 ScottA 200 200
b
L. monocytogenes FRDC 1039 400 200
b
L. monocytogenes FRDC 88571 400 200
b
Listeria murrayi ATCC 25420 200 200
b
L. murrayi HPB 30 400 200
b
Listeria ivanovii HPB 28 400 200
Listeria grayi ATCC 19120 800 200
Micrococcus luteus ATCC 272 11600 3200
Pediococcus acidilactici UL5 400 800
Staphylococcus aureus ATCC 6538 n.t. 0
S. aureus ATCC 25923 0 0
S. aureus ATCC 43300 200 0
S. aureus R621 200 0
Staphylococcus carnosus 1600 800
Streptococcus mutans 59.1 n.t. 200
b
S. mutans 123.1 200
d n.t.
Streptococcus sobrinus ATCC 27352 200 800
Streptococcus salivarius ATCC 25923 800 800
Streptococcus pyogenes ATCC 10389 200 0
Streptococcus suis serotype 2 400 0
ATCC (Manassas, VA, USA); HPB (Health Canada, Ottawa, ON, Canada); FRDC
(Agriculture and Agrifood Canada, Sainte-Hyacinthe, QC, Canada).
aNot tested.
bHazy inhibition zone was observed.
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Page 6 of 10S. mutans 59.1 of more than one mutacin in solid med-
ium having activity against Listeria spp.. Also, resistance
to pediocin-like bacteriocins in Listeria species has
already been reported and can be physiologically or
genetically acquired [28,29]. Low levels of resistance are
caused by alterations in membrane lipid composition
while high resistance levels involved the loss of a man-
nose permease component [30,31].
Nisin resistance is also reported and is related to mem-
brane composition [32] or alterations in the cell wall
[33]. Our results show that nisin-resistant Listeria strains
were still sensitive to the lantibiotic mutacin D-123.1.
Lipid II-targeted lantibiotics that are too short to form a
pore across the bilayer membrane can still maintain their
antibacterial activity to be able to kill the nisin-resistant
strains In a similar manner, mutacin D-123.1 could act
by trapping lipid II from the septum, blocking peptido-
glycan synthesis and leading to cell death [34]. Moreover,
activity of mutacin D-123.1 against antibiotic-resistant
Enterococcus spp. and Staphylococcus spp. stresses its
potential as a new antibiotic. Weak activity of mutacins
F-59.1 and D-123.1 were observed against their respec-
tive producing strains (S. mutans 59.1 and 123.1) as com-
pared to the highly sensitive strain M. luteus ATCC 272,
which suggests that the respective strains are able to pro-
duce specific self-immunity factors. Bacteriocin biosynth-
esis genes are generally co-transcribed with a gene
encoding a cognate immunity protein ensuring protec-
tion of the producing cell against the lethal activity of the
bacteriocin they produce [4].
Pediocin-like bacteriocins were identified in a wide
variety of Gram positive bacteria such as Bacillus spp.,
Carnobacterium spp., Enterococcus spp., Lactobacillus
spp., Leuconostoc spp., Listeria spp. [2,13]. While high
heterogeneity has been observed in the genetic determi-
nants coding for production of mutacins [12,35], this is
the first report of a pediocin-like mutacin produced by
S. mutans, which further extends the distribution of
pediocin-encoding genes as well as the antibacterial
spectra of S. mutans against pathogens sensitive to class
IIa bacteriocins. From the two genomes of S. mutans
strains available in public databases (UA159 in GenBank
under accession number AE014133 and NN2025 in the
DNA databank of Japan under accession number
AP010155) [17,36], no lantibiotic nor pediocin-like bac-
teriocin sequences were found, although many bacterio-
cin-related genes are detected [6]. Only some entries
with bacteriocin_II superfamily proteins (pfam01721) in
the NCBI database matched two pediocin family pro-
teins from Streptococcus bovis ATCC 700338 and Strep-
tococcus mitis ATCC 6249 (EFM26697.1 and
EFM30880.1). To our knowledge, only a Streptococcus
uberis strain was shown to produce a pediocin-like bac-
teriocin named ubericin A [37]. Production of
bacteriocins is widely distributed among strains of S.
mutans. Lantibiotic-type mutacin production is sporadi-
cally detected from strains isolated from different ori-
gins; this strongly suggests the existence of a common
genomic ancestor element for lantibiotic biosynthesis
[6]. Comparative genomic analysis reported that dispen-
sable genes exist and have been scattered through hori-
zontal genetic transfer in various S. mutans strains.
These optional mobile genes may be selected when they
provide competitiveness to the strains as in the case of
bacteriocin production to compete with the numerous
other bacterial species resident in the oral cavity [38].
Conclusion
Two bacteriocins from S. mutans have been isolated and
characterised in terms of molecular mass, sequence and
activity spectra. Mutacin F-59.1 is related to pediocin-
like bacteriocins and is the first one shown to be pro-
duced by S. mutans. Mutacin D-123.1 appears identical
to mutacin I in molecular mass and in the N-terminus
sequence. Antibacterial activity spectra of these muta-
cins indicate promising potential application by inhibit-
ing numerous bacterial pathogens. More research
remains to be done to increase the low yields of mutacin
production and purification.
Methods
Bacterial strains and media
Streptococcus mutans 59.1 and 123.1 produce mutacins
F-59.1 and D-123.1 respectively [8]. Micrococcus luteus
ATCC 272 (ATCC, Manassas, VA, USA) was used as
the indicator strain for the mutacin activity assays. All
bacteria were routinely grown aerobically at 37°C in
TSBYE made of TSB (Difco laboratories, Detroit, MI,
USA) supplemented with 0.3% yeast extract (Becton
Dickinson & Co., Cockeysville, MD, USA) or on TSAYE
plates made of TSA (Difco) enriched with 0.3% yeast
extract. Lactobacillus salivarius strain (provided by Syl-
vain Moineau, Université Laval, Québec, QC, Canada)
was cultivated aerobically at 30°C in MRS medium
(Oxoid, Nepean, ON, Canada). Other bacterial strains
used for the inhibitory spectra determination are
described in Mota-Meira et al. [7] and Morency et al.
[8]. Staphylococcus carnosus w a so b t a i n e df r o mt h e
strain collection of the Department of Microbiology,
Biochemistry and Bioinformatics (Université Laval).
Production of mutacins
An overnight culture of the producing strain Streptococ-
cus mutans 59.1 in TSBYE was used to inoculate (1% v/
v) 2 L of supplemented whey permeate (SWP) consist-
ing of cheese whey permeate 6% (w/v) (kind gift from
Agropur Coop., Granby, QC, Canada) supplemented
with 1% CaCO3 (Anachemia, Montréal, QC, Canada)
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Canada). The culture was incubated 48 h at 37°C under
aerobic conditions, centrifuged at 10 000 × g for 10 min
and the supernatant was heated at 70°C for 10 min to
destroy the remaining cells and enzyme activity [14].
Mutacin D-123.1 was produced in TSBYE (Difco) con-
taining 0.5% agarose (Difco). Batches of this medium
(4 L) were stab inoculated with a culture of S. mutans
123.1 grown in TSBYE and incubated for 72 h at 37°C.
After growth, the culture was scraped, aliquoted into
centrifuge bottles and frozen overnight at -20°C. The
bottles were then centrifuged at 4000 × g for 60 min
and 8000 × g for 30 min at room temperature. The
resulting supernatant was filtered through glass fibers
and Whatman no. 1 filter paper to remove agarose fines
then stored at 4°C.
Purification of mutacins
Purification of the two mutacins was achieved by two
hydrophobic chromatography steps as previously
described [15,39] by replacing TFA with HCl (10 mM)
[40]. Briefly, the active preparation was loaded on a Sep-
Pak
® Vac 35 cc (10 g) t-C18 Cartridge (Waters Corpora-
t i o n ,M i l f o r d ,M A ,U S A ) .C a r t r i d g e sw e r ef i r s te q u i l i -
brated with 500 mL of methanol followed by 500 mL of
deionized distilled water. Antibacterial compounds were
eluted with successive steps of 500 mL of water:metha-
nol mixtures increasing the gradient of methanol by
10% from 0 to 100% in 10 mM HCl. This was carried
out at a flow rate of 1 mL/min and UV detection at
214 nm. The final purification step was carried out by
reverse phase chromatography (RP)-HPLC analysis
(Beckman Gold Model, Coulter Canada Inc., Missis-
sauga, ON, Canada) using an analytical C18 column
(Luna 5 μ C18(2), 250 × 4.6 mm, 4 × 3.0 mm, Phenom-
enex, Torrance, CA, USA). Elution was carried out with
solvent A (5% acetonitrile, 10 mM HCl) and solvent B
(60% acetonitrile, 10 mM HCl) and recorded at 214 nm.
The following program of elution was developed: 0 to
3 min, constant 100% A; 3 to 15 min, a linear gradient
from 100% A to 100% B; 15 to 20 min, constant 100%
B; 20 to 23 min, a linear gradient from 100% B to 100%
A. A flow rate of 1 mL/min was used. The column was
maintained at 39°C with a column heater. Active frac-
tions were manually collected, subsequently dried in a
Speed-Vac
® concentrator (Model SC110A, Savant
Instrument Inc. Farmingdale, NY, USA) and then kept
at -20°C until processing. Protein concentration in active
fractions was determined using the BioRad DC protein
assay (BioRad, Mississauga, ON, Canada).
Activity assay of mutacins
Mutacin activity was determined by the spot test using
Micrococcus luteus ATCC 272 as sensitive strain where
two-fold dilutions were prepared in acidified (pH 2)
peptone water (0.5%) [14]. Antibacterial activity spectra
of purified mutacins was tested against a panel of bac-
terial strains using the critical dilution method com-
bined with the spot test method as described previously
[14]. Briefly, overnight cultures of test strains in TSBYE
were diluted in fresh broth before inoculating 5 mL of
soft agar (0.75%) in order to obtain confluent lawns of
growth on TSAYE plates. Five μL of purified mutacins,
diluted in acidified (10 mM HCl) distilled water to pro-
mote solubility of the peptides, were deposited on the
lawn and allowed to dry before appropriate incubation.
Mutacin activity was expressed in AU/mL and corre-
sponds to the reciprocal of the highest dilution showing
a noticeable inhibition zone on the lawn [14].
Amino acid sequencing procedure
Alkaline ethanethiol derivatisation as described by
Meyer et al. [26] was performed prior to sequencing of
mutacins. Briefly, the purified sample was vacuum dried
and was dissolved in 30 μL of a derivatisation mixture
composed of 1.4 M ethanethiol and 0.5 M NaOH in
46% aqueous ethanol. The sample was then incubated
for 60 min at 50°C in limited oxygen atmosphere. The
reaction was stopped by the addition of 2 μLo fg l a c i a l
acetic acid (Sigma-Aldrich, St Louis, MO, USA) just
before sequencing. Pure mutacin B-Ny266 was used as
control for the Edman degradation with the alkaline
ethanethiol derivatisation procedure [39]. Automated
Edman degradation was performed on a protein sequen-
cer (ABI Procise cLC, Applied Biosystems, Foster City,
CA, USA) at the Biotechnology Research Institute
(Montréal, QC, Canada). Amino acids were identified by
capillary HPLC on a C18 0.8 × 150 mm column.
Characterisation of mutacins by bioinformatic analyses
Homology searches were carried out with the National
Center of Biotechnology Information (NCBI) using the
basic local alignment search tool for protein (BLAST-P)
with default parameters [41]. The constraint-based multi-
ple alignment tool (COBALT) from NCBI was used with
the default parameters to perform alignment. The primary
and secondary structures of the mutacin F-59.1 were ana-
lyzed by the ExPASy Proteomics Server http://ca.expasy.
org/tools/#proteome[42] and the SCRATCH protein pre-
dictor http://scratch.proteomics.ics.uci.edu/[43].
Molecular mass analysis
The molecular masses of mutacins (D-123.1 and F-59.1)
were determined from pure HPLC fractions by MALDI-
TOF MS analyses at the Mass Spectrometry Laboratory
of Molecular Medicine Research Centre (University of
Toronto, Toronto, ON, Canada). A saturated b-cyano-4-
hydroxycinnamic acid in 70% acetonitrile and 0.1% TFA
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ple was spotted on the sample target, and then 1 μLo f
saturated matrix solution was added on the top. After
the crystal was formed, the sample target was inserted
into the mass spectrometer. MALDI MS was acquired
in linear mode at positive on Applied Biosystems Voya-
ger-DE STR MALDI-TOF mass spectrometer (Applied
Biosystems, Foster City, CA, USA) equipped with a 337
nm laser. Acceleration voltage was set at 20 kV, grid
voltage at 94%, guide wire at 0.05%, and delay time at
175 nsec. The mass spectra were externally calibrated by
the molecular weights of a mixture of standard peptides.
The mass accuracy is typically 0.05%.
Protein sequence accession number
The protein sequence data of the mutacin F-59.1
appears in the UniProt Knowledgebase under the acces-
sion number P86386.
Inhibitory effect of mutacin F-59.1
One milliliter of active preparation (1600 AU/mL)
adjusted to pH 7.0 was filter sterilised then added to 10
mL of an early-log-phase culture of Micrococcus luteus
ATCC 272 grown in TSBYE. Bacterial culture in TSBYE
was used as a negative control. The viable count in
CFU/mL was determined at intervals for up to 24 h for
samples and control during incubation at 37°C by plat-
ing 100 μL of an appropriate dilution in peptone water
(0.1%) on TSAYE incubated at 37°C at least 24 h.
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